Can serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?

Figures & data

Table 1. Demographic features and laboratory parameters of study groups*.

	Group I (CVPC) n = 30	Group II (AVF) n = 30	Group III (Stage 3–4 CRF) n = 30	Group IV (Control group) n = 30	P
Age (year)	53.10 ± 10.23	51.40 ± 13.11	48.46 ± 9.93	50.26 ± 9.82	NS
Gender (F/M)	16/14	14/16	14/16	13/17	NS
Duration of HD (months)	28.06 ± 15.33	33.20 ± 18.21	–	–	NS
GFR (ml/)	§	§	34.27 ± 10.13	¶
Duration of CVPC (months)	10.33 ± 4.48	–	–	–
Kt/Vurea	1.33 ± 0.08	1.36 ± 0.06	–	–	NS
BMI (kg/m^2)	22.34 ± 2.85	22.44 ± 2.45	23.59 ± 2.21	23.40 ± 3.26	NS
Albumin (g/dl)	3.53 ± 0.35	4.02 ± 0.34	4.13 ± 0.27	4.61 ± 0.28	a,b,c,e,f
Haemoglobin (g/dl)	11.30 ± 0.84	11.58 ± 0.82	12.51 ± 1.11	13.46 ± 0.64	b,c,d,e,f
White blood cells (mm^3)	6741.33 ± 1872.15	6324.00 ± 1560.72	7042.66 ± 1452.08	6019.00 ± 1215.73	NS
Ferritin (ng/ml)	277.00 ± 73.65	233.93 ± 68.66	197.16 ± 40.92	100.96 ± 23.47	a,b,c,e,f
hs-CRP (ng/ml)	7115.76 ± 782.12	4239.10 ± 888.36	3464.53 ± 717.41	1730.70 ± 627.07	a,b,c,e,f
IL-6 (pg/ml)	4.85 ± 0.59	3.50 ± 0.48	3.03 ± 0.80	1.61 ± 0.24	a,b,c,d,e,f
TNF-α (pg/ml)	17.70 ± 1.20	15.57 ± 2.17	12.37 ± 3.97	1.56 ± 0.65	a,b,c,d,e,f
NGAL (pg/ml)	7645.80 ± 924.61	4131.20 ± 609.871	3685.60 ± 481.08	1308,66 ± 371.12	a,b,c,d,e,f

Notes: *Data given means ± SD and n (%).

GFR: glomerular filtration rate; BMI: body mass index; hs-CRP: high sensitive-C reactive protein; TNF-α: tumor necrosis factor-alpha; IL-6: interleukin-6; NGAL: neutrophil gelatinase-associated lipocalin.

§: Anuric; ¶: Not calculated.

NS: non-significant; p > 0.05.

^aComparison between group I and group II is p < 0.05.

^bComparison between group I and group III is p < 0.05.

^cComparison between group I and group IV is p < 0.05.

^dComparison between group II and group III is p < 0.05.

^eComparison between group II and group IV is p < 0.05.

^fComparison between group III and group IV is p < 0.05.

Figure 1. Correlation between serum NGAL levels and duration of CVPC in HD patients.

Figure 2. Correlation between serum NGAL and hs-CRP level in HD patients.

Figure 3. Correlation between serum NGAL and TNF-alpha levels in HD patients.

Table 2. Correlation of serum NGAL levels with variables in all patients groups.

	Group I (CVPC)		Group II (AVF)		GroupIII (Stage3-4 CRF)
	r	p	r	p	r	p
Age	0.174	0.359	0.104	0.585	0.216	0.252
BMI	−0.226	0.231	0.235	0.211	0.177	0.349
WBC	−0.117	0.539	0.082	0.672	0.123	0.518
Kt/Vurea	0.272	0.147	0.043	0.823	NA	NA
Duration of HD	0.204	0.279	0.089	0.640	NA	NA
hs-CRP	0.470	0.002*	0.412	0.005*	0.457	0.011*
TNF-α	0.394	0.009*	0.417	0.002*	0.356	0.023*
IL-6	0.439	0.015*	0.522	0.008*	0.518	0.003*
Albumin	−0.527	0.008*	−0.418	0.002*	−0.336	0.001*
Duration of CVPC	0.739	0.000*	NA	NA	NA	NA

Notes: *Statistically significant.

NA: Not applicable.